MIP and tuberculosis: Another phase III randomized, double‐blind, placebo‐controlled, multicenter clinical trial sponsored by the Department of Science and Technology, India, and Cadila Pharmaceuticals Ltd. evaluated the therapeutic efficacy and safety of MIP in Indian Type II TB patients (NCT00265226).96